The possibility of effective using the conservative and the minimally invasive treatment methods at various stages of the Dupuytren disease
- Authors: Ovchinnikova E.K.1, Gilfanov S.I.1,2
-
Affiliations:
- Central State Medical Academy of Department of Presidential Affairs
- Central Clinical Hospital of the Management Affair of President Russian Federation
- Issue: Vol 15, No 4 (2024)
- Pages: 97-103
- Section: Reviews
- URL: https://journals.rcsi.science/clinpractice/article/view/278599
- DOI: https://doi.org/10.17816/clinpract641980
- ID: 278599
Cite item
Abstract
A literature review is presented on the conservative and minimally invasive methods of treating the Dupuytren contracture. The investigators discuss both the methods implemented into clinical practice and those, which are currently at the stage of clinical and laboratory trials, including the minimally invasive methods, which can be used not only at the later stages, but also in cases of early manifestations of the disease. Among them there are the combined use of conservative methods, the radiation therapy, the injections of collagenase and steroids, the use of immunodepressive medicines and the needle aponeurotomy. These methods can be used at the earliest stages of the disease, however, the absence of proper evidence base often hinders their wide implementation. Up to the present moment, there is no commonly acknowledged approach to managing and treating the patients with early stage of the disease. The modern approach is focused on the invasive treatment of only later disease stages and of the severe contracture cases. This is why we would like to emphasize the potential of minimally invasive methods at the early stages of the Dupuytren disease, as well as the necessity of further research in this direction along with the importance of implementing such methods into everyday practice of the physicians.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina K. Ovchinnikova
Central State Medical Academy of Department of Presidential Affairs
Email: Katrin21101@mail.ru
ORCID iD: 0009-0006-5915-9616
Russian Federation, Moscow
Sergey I. Gilfanov
Central State Medical Academy of Department of Presidential Affairs; Central Clinical Hospital of the Management Affair of President Russian Federation
Author for correspondence.
Email: Gilfanov63@rambler.ru
ORCID iD: 0009-0006-3600-1752
MD, PhD, Professor
Russian Federation, Moscow; MoscowReferences
- Selles RW, Zhou C, Kan HJ, et al. Percutaneous aponeurotomy and lipofilling versus limited fasciectomy for Dupuytren’s contracture: 5-year results from a randomized clinical trial. Plast Reconstr Surg. 2018;142(6):1523–1531. doi: 10.1097/PRS.0000000000004982
- Salari N, Heydari M, Hassanabadi M, et al. The worldwide prevalence of the Dupuytren disease: A comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020;15(1):495. doi: 10.1186/s13018-020-01999-7
- Boe C, Blazar P, Iannuzzi N. Dupuytren contractures: An update of recent literature. J Hand Surg Am. 2021;46(10):896–906. doi: 10.1016/j.jhsa.2021.07.005
- Kemler MA, de Wijn RS, van Rijssen AL, et al. Dutch multidisciplinary guideline on Dupuytren disease. J Hand Surg Glob Online. 2022;5(2):178–183. doi: 10.1016/j.jhsg.2022.11.008
- Nanchahal J, Chan JK. Treatments for early-stage Dupuytren’s disease: An evidence-based approach. J Hand Surg Eur Vol. 2023;48(3):191–198. doi: 10.1177/17531934221131373
- Taheri P, Salek N, Mousavi M, Maghroori R. The effect of shock wave therapy on improving the symptoms and function of patients with Dupuytren’s contracture. Adv Biomed Res. 2022;11:3. doi: 10.4103/abr.abr_155_21
- Finney R. Dupuytren’s contracture. Br J Radiol. 1955;28(335):610–614. doi: 10.1259/0007-1285-28-335-610
- Ruettermann M, Hermann RM, Khatib-Chahidi K, Werker PM. Dupuytren’s Disease-etiology and treatment. Dtsch Arztebl Int. 2021;118(46):781–788. doi: 10.3238/arztebl.m2021.0325
- Peimer CA, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year data. J Hand Surg Am. 2015;40(8):1597–1605. doi: 10.1016/j.jhsa.2015.04.036
- Ball C, Izadi D, Verjee LS, et al. Systematic review of non-surgical treatments for early Dupuytren’s disease. BMC Musculoskelet Disord. 2016;17(1):345. doi: 10.1186/s12891-016-1200-y
- Nayar SK, Pfisterer D, Ingari JV. Collagenase clostridium histolyticum injection for dupuytren contracture: 2-year follow-up. Clin Orthop Surg. 2019;11(3):332–336. doi: 10.4055/cios.2019.11.3.332
- Coleman S, Gilpin D, Kaplan FT, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39(1):57–64. doi: 10.1016/j.jhsa.2013.10.002
- Fenney R. Dupuytren’s contracture a radiotherapeutic approach. Lancet. 1953;265(6795):1064–1066. doi: 10.1016/s0140-6736(53)90669-2
- Zachariae L, Zachariae F. Hydrocortisone acetate in the treatment of Dupuytren’s contraction and allied conditions. Acta Chir Scand. 1955;109(6):421–431.
- Corsi M. [Radiotherapy of Dupuytren’s disease. (In Italian)]. Friuli Med. 1966;21(3):391–403.
- Ketchum LD, Donahue TK. The injection of nodules of Dupuytren’s disease with triamcinolone acetonide. J Hand Surg. 2000;25(6):1157–1162. doi: 10.1053/jhsu.2000.18493
- Shelley WB, Shelley ED. Response of Dupuytren’s contracture to high-potency topical steroid. Lancet. 1993;342(8867):366. doi: 10.1016/0140-6736(93)91507-i
- Verjee LS, Midwood K, Davidson D, et al. Myofibroblast distribution in Dupuytren’s cords: Correlation with digital contracture. J Hand Surg Am. 2009;34(10):1785–1794. doi: 10.1016/j.jhsa.2009.08.005
- Verjee LS, Verhoekx JS, Chan JK, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci USA. 2013;110(10):E928–937. doi: 10.1073/pnas.1301100110
- Nanchahal J, Ball C, Davidson D, et al. Anti-tumour necrosis factor therapy for dupuytren’s disease: A randomised dose response proof of concept phase 2a clinical trial. EBioMedicine. 2018;33:282–288. doi: 10.1016/j.ebiom.2018.06.022
- Zhou C, Liu F, Gallo PH, et al. Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts. BMC Musculoskelet Disord. 2016;17(1):469. doi: 10.1186/s12891-016-1326-y
- Патент РФ на изобретение № RU 2570769 C1. Бюл. № 34. Жигало А.В., Шаповалов В.М., Стадниченко С.Ю. Способ лечения контрактуры Дюпюитрена. [Patent RUS № RU 2570769 C1. Bull No. 34. Zhigalo AV, Shapovalov VM, Stadnichenko SY. Method of treatment of Dupuytren’s contracture. (In Russ.)] Режим доступа: https://patenton.ru/patent/RU2570769C1?ysclid=m4vpl6kbyk764660666. Дата обращения: 15.11.2024. EDN: LZHMJO
- Beaudreuil J, Lellouche H, Orcel P, Bardin T. Need for a standard procedure for needle aponeurotomy, consensus definition of recurrence, and functional assessment in Dupuytren disease. Plast Reconstr Surg. 2012;130(1):200e–201e. doi: 10.1097/PRS.0b013e318254feb5
- Kan HJ, Selles RW, van Nieuwenhoven CA, et al. Percutaneous aponeurotomy and lipofilling (PALF) versus limited fasciectomy in patients with primary Dupuytren’s contracture: A prospective, randomized, controlled trial. Plast Reconstr Surg. 2016;137(6):1800–1812. doi: 10.1097/PRS.0000000000002224
- Петренко А.Ю., Иванов Э.Н., Петренко Ю.А. Стволовые клетки из жировой ткани // Biotechnologia Acta. 2008. Т. 1, № 4. С. 039–049. [Petrenko AYu, Ivanov EM, Petrenko YuO. Stem cells of adipose tissue. Biotechnologia Acta. 2008;1(4):039–049]. EDN: PXUZLF
- Богов А.А., Муллин Р.И., Филиппов В.Л., и др. Результаты применения игольчатой апоневротомии в сочетании с липофилингом в лечении контрактуры Дюпюитрена // Практическая медицина. 2016. № 4-1. С. 59–62. [Bogov AA, Mullin RI, Filippov VL, et al. Results of using needle aponeurotomy in combination with lipofilling in the treatment of Dupuytren’s contracture. Practical Medicine. 2016;(4-1):59–62]. EDN: WKBFYH
Supplementary files
